



## Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

---

### **P4.25: COMPARISON BETWEEN EFFECTS OF BEZAFIBRATE AND EICOSAPENTAENOIC ACID ON ARTERIAL STIFFNESS MONITORING WITH CARDIO-ANKLE VASCULAR INDEX**

Takashi Yamaguchi, Saiki Atsuhito, Tatsuno Ichiro, Shirai Kohji

**To cite this article:** Takashi Yamaguchi, Saiki Atsuhito, Tatsuno Ichiro, Shirai Kohji (2013) P4.25: COMPARISON BETWEEN EFFECTS OF BEZAFIBRATE AND EICOSAPENTAENOIC ACID ON ARTERIAL STIFFNESS MONITORING WITH CARDIO-ANKLE VASCULAR INDEX, Artery Research 7:3\_4, 142–142, DOI: <https://doi.org/10.1016/j.artres.2013.10.143>

**To link to this article:** <https://doi.org/10.1016/j.artres.2013.10.143>

Published online: 14 December 2019

4.6±1.5 ng/ml;  $P<0.01$ ) and higher PWV (9.5±1.4 vs 8.4±1.3 m/s;  $P<0.001$ ). Kaplan–Meier survival curves for MACE by TT tertiles at baseline are shown in figure. Subjects in the lowest TT tertile (<4.0 ng/ml) had a statistically significant higher risk of MACE compared to those in the highest tertile (>4.9 ng/ml) in multivariate Cox models adjusted for age, systolic blood pressure and risk factors (all  $P<0.05$ ). Addition of TT to standard risk factors model yielded a net reclassification improvement of 38.8% ( $P<0.05$ ). In regression analysis, PWV was inversely associated with TT ( $\beta=-0.207$ ,  $P<0.001$ ), indicating deterioration of aortic stiffness with decreasing testosterone level.

**Conclusions:** The principal finding of our study is that androgen deficiency predicts independently MACE in long-term follow-up in hypertensive patients. The association of TT with aortic stiffness may suggest other mechanisms, such as changes in vascular function and structure.

#### P4.23

##### CORRECTION OF VITAMIN D DEFICIENCY BY CALCIFEDIOL IN HYPERTENSIVES WITH STAGE 3 CHRONIC KIDNEY DISEASE REDUCES PULSE WAVE VELOCITY BY LOWERING BLOOD PRESSURE

Rodilla Sala Enrique <sup>1,2</sup>, Costa Muñoz José Antonio <sup>1</sup>, Porcar Paula <sup>1</sup>, Pascual Izuel José María <sup>1,3</sup>, Malek Marín Tamara <sup>1</sup>

<sup>1</sup>Unidad HTA y Riesgo Vascular, Servicio Medicina Interna, Hospital de Sagunto, Sagunto, Spain

<sup>2</sup>Facultad de Ciencias de la Salud, Universidad Cardenal Herrera, Castellón, Castellón, Spain

<sup>3</sup>Facultad de Medicina, Universidad de Valencia, Valencia, Spain

**Objectives:** To measure the extent of correction of vitamin D deficiency and hyperparathyroidism after treatment with calcifediol as well as their relationship to blood pressure and arterial stiffness in hypertensive patients with stage 3 chronic kidney disease (CKD).

**Methods:** Longitudinal study that included 74 treated hypertensives (46 women, 62,2%) with stage 3 CKD (eGFR 47,7 ml/min, SD±10) without previous vitamin D supplementation treatment. Calcifediol 266 µg/2 weeks and calcium 600 mg/d were given if baseline-vitamin D < 30 ng/ml and < 9,5 mmol/l, respectively. A second visit took place after 4 months.

**Results:** The mean age was 72,9 years (SD±10). The prevalence of vitamin D deficiency decreased from initially 96% to 23% (mean baseline: 18, mean final: 42 ng/ml), and of secondary hyperparathyroidism from 62% to 37% (mean at baseline: 87, mean final: 63 pg/ml). There were no significant changes in eGFR, calcium or phosphor or number of antihypertensive drugs, but pulse wave velocity (measured with MOBILOGRAPH®) and BP decreased significantly from initially 133/76 to 123/72 ( $p<0.001$ ) mmHg and from 10,8 to 10,5 m/sec ( $p<0.005$ ), respectively. In bivariate analysis the difference between baseline and final vitamin D and PTH correlated significantly. The only variable significantly related to the change in PWV was the difference in peripheral SBP. Only one case of asymptomatic hypercalcemia was observed.

**Conclusions:** In hypertensive patients with stage 3 CKD, correction of vitamin D deficiency by oral calcifediol leads to a substantial reduction of incipient hyperparathyroidism and a significant decrease of arterial stiffness.

#### P4.24

##### DIETARY INORGANIC NITRATE LOWERS CENTRAL BLOOD PRESSURE

S. Kukadia, T. Tillin, E. Coady, N. Chaturvedi, A. D. Hughes  
International Centre for Circulatory Health, Imperial College London, London, United Kingdom

**Background:** Dietary inorganic nitrate is reduced to (nitric oxide) NO in the body. Beetroot is a rich source of dietary inorganic nitrate and has been shown to lower brachial blood pressure (BP) by this mechanism. The effect on aortic (central) BP, which may be a better predictor of cardiovascular disease, has not been studied.

**Objectives:** To measure the effect of dietary nitrate in beetroot juice on central BP at both 30 minutes and over a 6 hour period post-beetroot juice consumption.

**Method:** A double-blind, randomised, placebo-controlled crossover trial was performed in nine healthy, normotensive men and women aged between 22 and 45 years. Participants were randomised to receive beetroot juice (6.5-7.3 mmol nitrate) or placebo juice (0.04-0.06 mmol nitrate). Brachial and central BP were measured at baseline, 30 and 60 minutes post-ingestion, and at least hourly for the following 24 hours. Following a washout period, the procedure was repeated within seven days with

crossover to the opposite arm of the trial. There were no dietary restrictions during the study.

**Results:** Compared with placebo, beetroot juice lowered central systolic BP at 30 minutes (change in beetroot juice: -2.6±3.4 mmHg vs. change in placebo: 1.8±5.9 mmHg,  $P=0.045$ ). Beetroot juice also lowered central systolic BP averaged over 6 hours post-ingestion (beetroot: 106±8 mmHg vs. placebo: 111±11 mmHg,  $P=0.029$ ).

**Conclusion:** Consumption of beetroot juice lowered central BP. Beetroot juice could have a role in CV risk management in the general population, but further research is required to establish its long-term benefits, safety and tolerability.

#### P4.25

##### COMPARISON BETWEEN EFFECTS OF BEZAFIBRATE AND EICOSAPENTAENOIC ACID ON ARTERIAL STIFFNESS MONITORING WITH CARDIO-ANKLE VASCULAR INDEX

Takashi Yamaguchi <sup>1</sup>, Saiki Atsuhito <sup>1</sup>, Tatsuno Ichiro <sup>1</sup>, Shirai Kohji <sup>2</sup>

<sup>1</sup>Center of Diabetes, Endocrine and metabolism, Sakura Hospital, Chiba, Japan

<sup>2</sup>Dept. Vascular function, Sakura Hospital, Toho UNIV., Chiba, Japan

**Background:** Bezafibrate and Eicosapentanoic acid (EPA) were known to decrease serum triglyceride. And, EPA administration for 5 years was reported to improve cardiovascular events by JLIT study. Cardio-ankle vascular index (CAVI) was a new index reflecting arterial stiffness from the origin of the aorta to the ankle, and is reported to be a predictor of cardiac events or death rate of cardiovascular events. But, the effects of both agents on arterial stiffness were not fully clarified.

**Object:** The purpose of this paper is to clarify the effect of bezafibrate and EPA on the arterial stiffness monitored with CAVI in the type 2 diabetic patients with hypertriglyceridemia.

**Subjects and methods:** Eighty type 2 diabetic outpatients with hypertriglyceridemia were randomly divided into two groups: bezafibrate (BEZA; 400mg/day) and EPA (1800mg/day) groups and took each treatment for 6 months. Glucose and lipid metabolism, d-ROMs; an oxidative stress marker were also studied. CAVI was measured using Vasela1500 (Fukuda Denshi. Co.LTD).

**Results:** After 6 month treatment, blood pressure, LDL-cholesterol (LDL-C), CK were not significantly changed comparing with before values, in both groups. Triglyceride (TG) and remnant-like particle cholesterol decreased significantly in both groups, and there were no significant differences between groups. HDL-C, Apo A-1 increased and HbA1C, d-ROMs decreased significantly only in BEZA group. CAVI decreased by 0.1 in EPA group (not significant) and by 0.5 in BEZA group ( $p<0.005$ ). There was a significant difference in the changes of CAVI between both groups ( $p<0.05$ ). In BEZA group, there were no significant correlations between changes of CAVI and the changes of the other parameters.

**Conclusion:** Bezafibrate administration improved arterial stiffness monitored with CAVI significantly, whereas EPA administration did not change CAVI, in type 2 diabetic patients with hypertriglyceridemia.

#### P4.26

##### ASSOCIATIONS BETWEEN FGF23-LEVEL AND ARTERIAL DISTENSIBILITY IN CHRONIC KIDNEY DISEASE

O. Cseprekal <sup>1</sup>, Németh Zs <sup>3</sup>, A. Marton <sup>3</sup>, E. Vámos <sup>1</sup>, J. Nemcsik <sup>4</sup>, J. Egresits <sup>1</sup>, T. El Hajd Othmane <sup>1</sup>, B. Fekete <sup>1</sup>, Deák Gy <sup>3</sup>, I. Kiss <sup>2</sup>, A. Tislér <sup>1</sup>

<sup>1</sup>1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary

<sup>2</sup>St Imre Teaching Hospital, Division of Nephrology, Budapest, Hungary

<sup>3</sup>Uzsoki Hospital, Division of Nephrology, Budapest, Hungary

<sup>4</sup>Department of Family Medicine, Semmelweis University, Budapest, Hungary

Vascular calcification and hemodynamical abnormalities lead to reduced arterial elasticity in end stage renal disease. Fibroblast growth factor-23 (FGF23) predicts cardiovascular mortality in advance stages of renal failure possibly indicating more advanced vascular calcification. The relation of FGF23 to arterial stiffness in chronic kidney disease is currently under investigations.

The aim of our cross sectional study was to assess the potential associations between FGF23 and arterial distensibility.

FGF23 (ELISA), pulse wave velocity (PWV), augmentation index (AI) and central pulse pressure (CPP) (PulsePen), were measured in patients with